Literature DB >> 1370419

Altered function and surface marker expression of neutrophils induced by rhG-CSF treatment in severe congenital neutropenia.

J Elsner1, J Roesler, A Emmendörffer, C Zeidler, M L Lohmann-Matthes, K Welte.   

Abstract

Neutrophils from patients suffering from severe congenital neutropenia (SCN), who were receiving recombinant human granulocyte colony-stimulating factor (rhG-CSF), were investigated in order to analyze the previously described decrease in chemotaxis. This study demonstrated the decreased chemotaxis to five well-known chemoattractants, FMLP, C5a, IL-8, LTB4 and PAF. To further investigate this impairment of patients' neutrophils, receptors and receptor turnover for chemoattractants were examined using flow cytometry. We found 1) increased FMLP receptor and decreased C5a receptor expression, 2) a normal expression of intracellular FMLP receptors after incubation with PMA, 3) increased loss and decreased re-expression of FMLP receptors after incubation with this peptide, 4) normal expression of adhesion glycoproteins CR3 (CD11b/CD18) and LFA1 (CD11a/CD18), 5) further signs of in vivo preactivation: high expression of Fc gamma-RI (CD64) and Fc gamma-RII (CD32), decreased expression of Fc gamma-RIII (CD16), increased expression of CD14, and low expression of HLA-DR. These data demonstrate that the decrease of chemotaxis of neutrophils from SCN patients is not due: a) to a decrease in the number of intra- or extracellular FMLP receptors; b) to a decrease of adhesion molecules. However, the decreased chemotaxis could result from an altered FMLP receptor turnover. The relevance of the altered Fc gamma-receptor pattern for the in vivo occurrence of side-effects, e.g. the necrotic vasculitis, of G-CSF treatment is discussed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1370419     DOI: 10.1111/j.1600-0609.1992.tb01787.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  4 in total

Review 1.  Filgrastim. A review of its pharmacological properties and therapeutic efficacy in neutropenia.

Authors:  J E Frampton; C R Lee; D Faulds
Journal:  Drugs       Date:  1994-11       Impact factor: 9.546

2.  Severe congenital neutropenia in a multigenerational family with a novel neutrophil elastase (ELANE) mutation.

Authors:  Esther van de Vosse; Els M Verhard; Anton J T Tool; Adriëtte W de Visser; Taco W Kuijpers; Pieter S Hiemstra; Jaap T van Dissel
Journal:  Ann Hematol       Date:  2010-08-28       Impact factor: 3.673

3.  Leukocytoclastic vasculitis as a complication of recombinant granulocyte colony-stimulating factor therapy in a heart transplant patient.

Authors:  Giovanbattista Ippoliti; Marco Paulli; Marco Lucioni; Marinella Lauriola; Andrea Maria D'Armini
Journal:  Case Rep Transplant       Date:  2014-01-30

4.  A Case of Cutaneous Leukocytoclastic Vasculitis Associated with Granulocyte Colony-Stimulating Factor: An Unusual Presentation.

Authors:  Dokyoung Yoon; Hyun Jeong Byun; Se Jin Oh; Ji-Hye Park; Dong-Youn Lee
Journal:  Ann Dermatol       Date:  2020-03-11       Impact factor: 1.444

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.